Want to see AU:CMP full AI Analyst Report?
CMP Stock Chart & Stats
AU$0.34
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.34
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.23 - AU$0.45
Previous CloseN/A
Volume3.00K
Average Volume (3M)87.45K
Market Cap
AU$50.94M
Enterprise ValueAU$64.97M
Total Cash (Recent Filing)AU$2.00M
Total Debt (Recent Filing)AU$14.03M
Price to Earnings (P/E)637.5
Beta0.66
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)<0.01
Shares Outstanding199,761,750
10 Day Avg. Volume153,799
30 Day Avg. Volume87,448
Financial Highlights & Ratios
PEG Ratio-0.14
Price to Book (P/B)2.12
Price to Sales (P/S)0.91
P/FCF Ratio99.22
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.04
Revenue Forecast (FY)AU$80.10M
Bulls Say, Bears Say
Bulls Say
High Gross MarginA ~61% gross margin signals strong product-level economics and pricing power in diagnostic hardware/software. Durable margin support gives the company capacity to absorb SG&A, fund R&D and invest in consumables/services, improving long-term viability once operating leverage is achieved.
Diversified Revenue StreamsA mix of one-time capital equipment, recurring software/licenses, consumables and service contracts creates multiple cash levers. This reduces reliance on single sales cycles, increases customer stickiness via installed base upgrades, and supports steadier revenues over healthcare spending cycles.
Manageable LeverageModerate leverage (D/E ~0.64) suggests the balance sheet can support targeted investment, working capital and selective acquisitions without excessive solvency risk. For a med-device firm, this provides flexibility to invest in product development and geographic expansion while remaining within conservative debt levels.
Bears Say
Weak ProfitabilityNegative net margins and minimal EBIT indicate the company is not reliably converting revenues into sustainable operating profits. Persistent low profitability constrains reinvestment, limits ability to build reserves, and undermines long-term shareholder return unless structural cost or pricing improvements occur.
Poor Cash GenerationSeverely negative FCF growth and near-zero operating cash to income show material cash conversion problems. Weak cash generation raises refinancing risk, limits capacity to self-fund R&D/servicing of debt, and can force external financing or cutbacks, posing a durable threat to execution and growth plans.
Negative Return On EquityA negative ROE reflects an inability to generate returns on shareholder capital, signaling recurring losses or inefficient capital deployment. Over the medium term, sustained negative ROE erodes investor value and indicates the company must materially improve margins or restructure capital to restore long-term profitability.
Compumedics Limited News
CMP FAQ
What was Compumedics Limited’s price range in the past 12 months?
Compumedics Limited lowest share price was AU$0.23 and its highest was AU$0.45 in the past 12 months.
What is Compumedics Limited’s market cap?
Compumedics Limited’s market cap is AU$50.94M.
When is Compumedics Limited’s upcoming earnings report date?
Compumedics Limited’s upcoming earnings report date is Aug 27, 2026 which is in 56 days.
How were Compumedics Limited’s earnings last quarter?
Compumedics Limited released its earnings results on Feb 24, 2026. The company reported AU$0.001 earnings per share for the quarter, beating the consensus estimate of N/A by AU$0.001.
Is Compumedics Limited overvalued?
According to Wall Street analysts Compumedics Limited’s price is currently Overvalued.
Does Compumedics Limited pay dividends?
Compumedics Limited does not currently pay dividends.
What is Compumedics Limited’s EPS estimate?
Compumedics Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Compumedics Limited have?
Compumedics Limited has 199,761,750 shares outstanding.
What happened to Compumedics Limited’s price movement after its last earnings report?
Compumedics Limited reported an EPS of AU$0.001 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -2.353%.
Which hedge fund is a major shareholder of Compumedics Limited?
Currently, no hedge funds are holding shares in AU:CMP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Compumedics Limited Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
13.56%
12-Months-Change
Fundamentals
Return on Equity
0.48%
Trailing 12-Months
Asset Growth
13.30%
Trailing 12-Months
Company Description
Compumedics Limited
Compumedics Limited is a global medical technology enterprise engaged in the full lifecycle of designing, producing, marketing, and distributing advanced diagnostic medical devices. Its market reach extends across Australia, the Asia Pacific region, the Americas, Europe, and the Middle East. The company's product portfolio is primarily focused on solutions for sleep and neurological disorders. For sleep diagnostics, offerings include sophisticated PSG:EEG amplification systems like the Grael 4K, portable recording units such as the Somté PSG and Siesta 802, wearable monitoring devices like Somfit/Somfit Pro, and transcutaneous monitors (e.g., TCM5 FLEX). In the field of neurology, Compumedics supplies devices like the ONsight A.V.S. for home ambulatory studies, a variety of EEG amplifiers (e.g., Grael 4K-EEG, Grael LT EEG), comprehensive long-term EEG monitoring systems (Neuvo 64-512 Channel LTM), and specialized EMG/EP systems (including Xegis Forte and Xegis G:NEO). Complementing its hardware, the company develops an extensive range of software, featuring the Profusion Sleep and EEG platforms, Profusion neXus 360 (a web-based system for patient data and lab management), a Multi-Modal Neuroimaging Suite, and workflow optimization tools like Profusion neXus Laboratory Management and Scheduler. Other software offerings include HD Digital Video integration and various specialized applications. Furthermore, Compumedics provides magnetoencephalography systems, cutting-edge brain research technologies, services for pharmaceutical clinical trials and research, as well as a diverse array of accessories and consumables crucial for diagnostic and research endeavors. Established in 1987, Compumedics Limited is based in Abbotsford, Australia, and functions as a subsidiary of D & DJ Burton Holdings Pty Ltd.
Technical Analysis
Impedimed Limited
―
Somnomed Limited
―
Cyclopharm Limited
―
EMvision Medical Devices Ltd.
―
Control Bionics Ltd.
―